Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Which companies will likely produce the most COVID-19 vaccine in 2021? 

By Brian Buntz | February 5, 2021

Vaccine

Photo by Markus Spiske on Unsplash

Since the beginning of the pandemic, much of society has pinned its hopes on the availability of a vaccine. Now that several are available across the world, there is hope, said Dr. Anthony Fauci, chief medical advisor to President Joe Biden, in a recent JAMA interview. “There’s light at the end of the tunnel.” 

One thing that will make the light at the end of the tunnel brighter as we head into the spring is the greater availability of vaccine doses. “The discordance between supply and demand will be diminished,” Fauci said. 

The roster of companies producing vaccines is steadily increasing, making it possible to vaccinate a substantial portion of the world’s population this year. (Note: Most of the companies in this list have two-dose vaccines.) 

Here’s a roundup of notable companies’ production targets for 2021:

AstraZeneca and Oxford University: Up to 3 billion doses

In Nov. 2020, AstraZeneca (LON:AZN) projected it could produce up to 3 billion doses of the COVID-19 vaccine in 2021. However, its deliveries to the EU have been slower than expected, resulting in a vaccine supply dispute. The company recently vowed to provide the EU an additional 9 million doses of its vaccine to resolve the dispute. 

Pfizer and BioNTech: 1.3 billion doses

In Nov. 2020, Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) projected they could produce up to 1.3 billion doses this year. They recently bumped up that figure to 2 billion. Pfizer has projected vaccine sales will generate $15 billion in revenue in 2021. 

Production in early 2021 was slower than expected in Europe, but the two companies have reported that their production capacity has been restored. 

Johnson & Johnson: 1 billion doses

Johnson & Johnson (NYSE:JNJ) aims to produce 1 billion doses this year and expand production after that. The company has committed to not-for-profit pricing during the pandemic assuming its single-dose vaccine is authorized by FDA and other regulators. JNJ is also investigating a two-dose regimen for its vaccine. 

Sinovac: Approximately 1 billion doses

The China-based vaccine maker Sinovac has the capacity to produce about 500 million doses of its CoronaVac COVID-19 vaccine. But this month, the company could double its annual production capacity to 1 billion doses.

Sinopharm: 1 billion doses

The chairman of Sinopharm (OTCMKTS:SHTDY), Yang Xiaoyun, has said that the company could produce one billion doses of its two-dose vaccine this year.

Gameleya Center: 1 billion doses

The Russian research center stated last year that it planned on producing 1 billion vaccine doses in 2021. Recent data suggest the vaccine offers 91.6% efficacy, making it one of the most efficacious COVID-19 vaccines available.

Moderna: 600 million to 1 billion doses

Moderna (NSDQ:MRNA) increased its 2021 production target early in 2021 to 600 million doses. The company had projected an earlier minimum of 500 million doses. With sufficient hiring and investments, the firm could produce 1 billion doses this year. 

NovaVax: At least 1 billion doses

Novavax (NSDQ:NVAX) has stated that it can produce more than 2 billion doses annually “when all planned capacity has been brought online by mid-2021.”

A partnership with the Serum Institute of India will yield a projected 1 billion doses of its NVX-CoV2373 vaccine in 2021.

CureVac: Up to 300 million doses

CureVac (NSDQ:CVAC) aims to produce roughly 300 million vaccine doses in 2021. A collaboration with Bayer could help it boost capacity in 2022. GlaxoSmithKline (NYSE:GSK) has agreed to help the company make up to 100 million doses of CureVac’s mRNA vaccine. The two companies will also collaborate on a next-gen vaccine. 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE